Mishra Kavita K, Puri Dev R, Missett Brian T, Lamborn Kathleen R, Prados Michael D, Berger Mitchel S, Banerjee Anuradha, Gupta Nalin, Wara William M, Haas-Kogan Daphne A
Brain Tumor Research Center and Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.
Neuro Oncol. 2006 Apr;8(2):166-74. doi: 10.1215/15228517-2005-011. Epub 2006 Feb 22.
The purpose of this study was to assess the impact of early radiation therapy and extent of surgical resection on progression-free survival (PFS) and overall survival (OS) in children with WHO grade II low-grade gliomas (LGGs). We conducted a historical cohort study of 90 patients, ages 21 or younger, diagnosed with WHO grade II LGGs between 1970 and 1995. Median follow-up for surviving patients was 9.4 years (range, 0.5-22.6 years). Tests for variables correlating with OS and PFS were conducted by using log-rank tests and Cox proportional hazards models. Eleven patients underwent gross total resections (GTRs), 43 had subtotal resections, and 34 underwent biopsy only at diagnosis. Two patients underwent biopsy at time of recurrence. Of the 90 patients, 52 received radiation as part of their initial therapy following diagnosis (early-RT group). The overall five-year PFS and OS rates +/- SE were 56% +/- 5% and 90% +/- 3%, respectively. Ten-year PFS and OS rates were 42% +/- 6% and 81% +/- 5%, respectively. For patients older than three years and without GTRs, administration of early radiation did not appear to influence PFS or OS (P = 0.98 and P = 0.40, respectively; log-rank test). This was confirmed by multivariate analyses (P = 0.95 and P = 0.33 for PFS and OS, respectively). Of the 11 patients with GTRs, disease progressed in only two, and all were alive with no evidence of disease at last follow-up. Patients who underwent GTRs had significantly longer PFS (P = 0.02), but did not have significantly improved OS. Excellent long-term survival rates were achieved for children with WHO grade II LGGs. We were unable to demonstrate a benefit for administering radiation as part of initial treatment. An outcome benefit was seen with greater extent of resection.
本研究的目的是评估早期放射治疗及手术切除范围对世界卫生组织(WHO)二级低级别胶质瘤(LGG)患儿无进展生存期(PFS)和总生存期(OS)的影响。我们对90例年龄在21岁及以下、于1970年至1995年间被诊断为WHO二级LGG的患者进行了一项历史性队列研究。存活患者的中位随访时间为9.4年(范围:0.5 - 22.6年)。通过对数秩检验和Cox比例风险模型对与OS和PFS相关的变量进行检验。11例患者接受了全切除(GTR),43例进行了次全切除,34例在诊断时仅接受了活检。2例患者在复发时接受了活检。在这90例患者中,52例在诊断后接受了放射治疗作为初始治疗的一部分(早期放疗组)。总体五年PFS和OS率±标准误分别为56%±5%和90%±3%。十年PFS和OS率分别为42%±6%和81%±5%。对于年龄大于3岁且未接受GTR的患者,早期放疗似乎并未影响PFS或OS(P分别为0.98和0.40;对数秩检验)。多因素分析证实了这一点(PFS和OS的P分别为0.95和0.33)。在11例接受GTR的患者中,仅2例疾病进展,所有患者在最后一次随访时均存活且无疾病证据。接受GTR的患者PFS显著更长(P = 0.02),但OS并未显著改善。WHO二级LGG患儿实现了出色的长期生存率。我们未能证明将放射治疗作为初始治疗的一部分有何益处。切除范围越大,预后越好。